Anubis Barcelona New Even

Lactic Acid, Citric Acid, Glycolic Acid


Anubis Cosmetics Sl
Human Otc Drug
NDC 83021-033
Anubis Barcelona New Even also known as Lactic Acid, Citric Acid, Glycolic Acid is a human otc drug labeled by 'Anubis Cosmetics Sl'. National Drug Code (NDC) number for Anubis Barcelona New Even is 83021-033. This drug is available in dosage form of Lotion. The names of the active, medicinal ingredients in Anubis Barcelona New Even drug includes .alpha.-hexylcinnamaldehyde - .0150375 g/250mL Allantoin - .75 g/250mL Benzoic Acid - .625 g/250mL Dehydroacetic Acid - .25 g/250mL Diethylene Glycol Monoethyl Ether - .75 g/250mL Fd&c Blue No. 1 - .0005 g/250mL Fragrance 13576 - .075 g/250mL Glycolic Acid - 1.220625 g/250mL Lactic Acid - 2.348125 g/250mL Limonene, (+)- - .022755 g/250mL and more. The currest status of Anubis Barcelona New Even drug is Active.

Drug Information:

Drug NDC: 83021-033
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Anubis Barcelona New Even
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Lactic Acid, Citric Acid, Glycolic Acid
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Anubis Cosmetics Sl
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Lotion
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:.ALPHA.-HEXYLCINNAMALDEHYDE - .0150375 g/250mL
ALLANTOIN - .75 g/250mL
BENZOIC ACID - .625 g/250mL
DEHYDROACETIC ACID - .25 g/250mL
DIETHYLENE GLYCOL MONOETHYL ETHER - .75 g/250mL
FD&C BLUE NO. 1 - .0005 g/250mL
FRAGRANCE 13576 - .075 g/250mL
GLYCOLIC ACID - 1.220625 g/250mL
LACTIC ACID - 2.348125 g/250mL
LIMONENE, (+)- - .022755 g/250mL
LINALOOL, (+/-)- - .0041025 g/250mL
PHENOXYETHANOL - 2.5 g/250mL
POLYOXYL 40 HYDROGENATED CASTOR OIL - 1.25 g/250mL
PROPYLENE GLYCOL - 10.5 g/250mL
TROLAMINE - .5 g/250mL
WATER - 228.15635 mL/250mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 13 Oct, 2022
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 04 May, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: M016
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:ANUBIS COSMETICS SL
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
NUI:N0000175806
N0000175807
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:7X6O37OK2I
344S277G0Z
8SKN0B0MIM
2KAG279R6R
A1A1I8X02B
H3R47K3TBD
5EM498GW35
0WT12SX38S
33X04XA5AT
GFD7C86Q1W
D81QY6I88E
HIE492ZZ3T
7YC686GQ8F
6DC9Q167V3
9O3K93S3TK
059QF0KO0R
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class MOA:Ammonium Ion Binding Activity [MoA]
Mechanism of action of the drug—molecular, subcellular, or cellular functional activity—of the drug’s established pharmacologic class. Takes the form of the mechanism of action, followed by `[MoA]` (such as `Calcium Channel Antagonists [MoA]` or `Tumor Necrosis Factor Receptor Blocking Activity [MoA]`.
Pharmacologic Class EPC:Nitrogen Binding Agent [EPC]
Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`.
Pharmacologic Class:Acidifying Activity [MoA]
Ammonium Ion Binding Activity [MoA]
Nitrogen Binding Agent [EPC]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
83021-033-01250 mL in 1 BOTTLE, SPRAY (83021-033-01)13 Oct, 2022N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Ne lotion purpose

Product Elements:

Anubis barcelona new even lactic acid, citric acid, glycolic acid fd&c blue no. 1 fd&c blue no. 1 lactic acid lactic acid polyoxyl 40 hydrogenated castor oil polyoxyl 40 hydrogenated castor oil trolamine trolamine .alpha.-hexylcinnamaldehyde .alpha.-hexylcinnamaldehyde linalool, (+/-)- linalool, (+/-)- benzoic acid benzoic acid phenoxyethanol phenoxyethanol citric acid monohydrate glycolic acid glycolic acid sodium hydroxide propylene glycol propylene glycol water water allantoin allantoin dehydroacetic acid dehydroacetic acid diethylene glycol monoethyl ether diethylene glycol monoethyl ether fragrance 13576 fragrance 13576 limonene, (+)- limonene, (+)-

Indications and Usage:

Ne lotion indications

Warnings:

Ne lotion warnings

Do Not Use:

Ne lotion warnings

Dosage and Administration:

Ne lotion dosage

Package Label Principal Display Panel:

Ne lotion display panel


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.